Literature DB >> 8296480

Oral immunization with recombinant BCG induces cellular and humoral immune responses against the foreign antigen.

M Lagranderie1, A Murray, B Gicquel, C Leclerc, M Gheorghiu.   

Abstract

It has been shown recently that BCG can be used as a live recombinant vaccine to stimulate immune responses. Proliferative or cytotoxic T-cell responses against several viral proteins such as HIV Gag, Env or Nef were obtained after parenteral immunization with BCG expressing these proteins. Antibody responses were also obtained after immunization of mice with recombinant BCG strain which expressed lac Z under the control of a promoter sequence isolated from Mycobacterium paratuberculosis. We have used this recombinant vaccine in guinea-pigs to investigate the influence of various routes of immunization on the immunogenicity of a foreign antigen expressed by recombinant BCG. Guinea-pigs were immunized by oral, respiratory or intradermal routes and proliferative responses, delayed-type hypersensitivity and antibody responses specific for beta-galactosidase were followed for 16 weeks. Results demonstrated that humoral and cellular immune responses specific for beta-galactosidase can be produced in all groups of guinea-pigs. However, the respiratory and especially the oral route of administration induced higher local and systemic immune responses than the intradermal route of immunization. Moreover, the oral immunization of mice with this recombinant BCG induced IgA responses which could be detected in both sera and intestinal secretions. Therefore, this study demonstrates for the first time that oral immunization with recombinant BCG can induce strong cellular and humoral immune responses.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8296480     DOI: 10.1016/0264-410x(93)90096-g

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  14 in total

Review 1.  Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?

Authors:  Juan I Moliva; Joanne Turner; Jordi B Torrelles
Journal:  Vaccine       Date:  2015-08-28       Impact factor: 3.641

2.  Oral immunization with recombinant Mycobacterium bovis BCG simian immunodeficiency virus nef induces local and systemic cytotoxic T-lymphocyte responses in mice.

Authors:  M Lagranderie; A M Balazuc; B Gicquel; M Gheorghiu
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

3.  Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains.

Authors:  M R Lagranderie; A M Balazuc; E Deriaud; C D Leclerc; M Gheorghiu
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

4.  Genetic control of antibody responses induced by recombinant Mycobacterium bovis BCG expressing a foreign antigen.

Authors:  M Lagranderie; R Lo-Man; E Dériaud; B Gicquel; M Gheorghiu; C Leclerc
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

5.  Commensal Streptococcus mitis is a unique vector for oral mucosal vaccination.

Authors:  Nada Daifalla; Mark J Cayabyab; Emily Xie; Hyeun Bum Kim; Saul Tzipori; Philip Stashenko; Margaret Duncan; Antonio Campos-Neto
Journal:  Microbes Infect       Date:  2014-12-15       Impact factor: 2.700

6.  Protection of sheep against caseous lymphadenitis by use of a single oral dose of live recombinant Corynebacterium pseudotuberculosis.

Authors:  A L Hodgson; M Tachedjian; L A Corner; A J Radford
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

7.  Oral delivery of Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in mice.

Authors:  Frank E Aldwell; Ian G Tucker; Geoffrey W de Lisle; Bryce M Buddle
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

8.  Mycobacterium bovis BCG priming induces a strong potentiation of the antibody response induced by recombinant BCG expressing a foreign antigen.

Authors:  M Gheorghiu; M R Lagranderie; B M Gicquel; C D Leclerc
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

Review 9.  Reassessment of the impact of mucosal immunity in infection with the human immunodeficiency virus (HIV) and design of relevant vaccines.

Authors:  J Mestecky; S Jackson
Journal:  J Clin Immunol       Date:  1994-09       Impact factor: 8.317

10.  Pre-clinical development of BCG.HIVA(CAT), an antibiotic-free selection strain, for HIV-TB pediatric vaccine vectored by lysine auxotroph of BCG.

Authors:  Narcís Saubi; Alice Mbewe-Mvula; Ester Gea-Mallorqui; Maximillian Rosario; Josep Maria Gatell; Tomáš Hanke; Joan Joseph
Journal:  PLoS One       Date:  2012-08-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.